4.7 Article

Erectile Dysfunction and Later Cardiovascular Disease in Men With Type 2 Diabetes

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 56, 期 23, 页码 1908-1913

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2010.04.067

关键词

coronary heart disease; epidemiology; erectile dysfunction; stroke

资金

  1. Servier Laboratories
  2. National Health and Medical Research Council of Australia
  3. Medical Research Council
  4. Chief Scientist Office at the Scottish Government Health Directorates
  5. Biotechnology and Biological Sciences Research Council
  6. Engineering and Physical Sciences Research Council
  7. Economic and Social Research Council
  8. Institut Servier and Assistance Publique-Hopitaux de Paris
  9. Pfizer
  10. Roche
  11. Takeda
  12. Pepsico
  13. Amgen
  14. AstraZeneca
  15. GlaxoSmithKline
  16. Sanofi-Aventis
  17. Servier
  18. Tanabe
  19. Johnson Johnson
  20. Merck Schering Plough
  21. United Healthcare Group
  22. National Heart Foundation of Australia
  23. Dr. Reddy's laboratories
  24. Abbott
  25. Merck Frosst
  26. Bristol-Myers Squibb
  27. Novartis
  28. Bayer
  29. CIHR
  30. CFI
  31. Canada Research Center
  32. Genome Canada/Quebec
  33. Memorium
  34. University of Edinburgh as part of the cross-council Lifelong Health and Wellbeing initiative
  35. MRC [MC_U130059821] Funding Source: UKRI
  36. Medical Research Council [MC_U130059821] Funding Source: researchfish

向作者/读者索取更多资源

Objectives The aim of this study was to examine the relationship between erectile problems in men and cardiovascular disease (CVD) mortality. Background Although there are plausible mechanisms linking erectile dysfunction (ED) with coronary heart disease (CHD) and stroke, studies are scarce. Methods In a cohort analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial population, 6,304 men age 55 to 88 years with type 2 diabetes participated in a baseline medical examination when inquiries were made about ED. Over 5 years of follow-up, during which study members attended repeat clinical examinations, the presence of fatal and nonfatal CVD outcomes, cognitive decline, and dementia was ascertained. Results After adjusting for a range of covariates, including existing illness, psychological health, and classic CVD risk factors, relative to those who were free of the condition, baseline ED was associated with an elevated risk of all CVD events (hazard ratio: 1.19; 95% confidence interval: 1.08 to 1.32), CHD (hazard ratio: 1.35; 95% confidence interval: 1.16 to 1.56), and cerebrovascular disease (hazard ratio: 1.36; 95% confidence interval: 1.11 to 1.67). Men who experienced ED at baseline and at 2-year follow-up had the highest risk for these outcomes. Conclusions In this cohort of men with type 2 diabetes, ED was associated with a range of CVD events. (J Am Coll Cardiol 2010;56:1908-13) (C) 2010 by the American College of Cardiology Foundation

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据